Immunology News and Research

Latest Immunology News and Research

Cardiome Pharmam, Astellas Pharma begin patient enrolment for ACT 5 trial

Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that patient enrolment has begun for the ACT 5 trial, a confirmatory Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection, a drug product candidate under development for the rapid conversion of atrial fibrillation to sinus rhythm.

29 Oct 2009

USC researchers receive grant to develop stem cell-based treatment for age-related macular degeneration

Physician-researchers at the University of Southern California (USC) received a nearly $16 million grant from the California Institute of Regenerative Medicine (CIRM) to fund the development of a stem cell-based treatment for age-related macular degeneration, the leading cause of vision loss and blindness among the elderly.

29 Oct 2009

Pregnant women with symptoms of depression have a stronger biological reaction to the seasonal flu vaccine

Pregnant women with significant symptoms of depression tend to have a stronger biological reaction to the seasonal flu vaccine than do women with lower depression levels, according to a new study.

29 Oct 2009

Lovelace Respiratory Research Institute and Brigham and Women's Hospital collaborate on respiratory diseases research

Lovelace Respiratory Research Institute (LRRI) recently announced the formation of a research agreement between the Division of Pulmonary and Critical Care Medicine of the Department of Medicine at Brigham and Women's Hospital (BWH), teaching hospital of Harvard Medical School in Boston.

28 Oct 2009

United States Patent and Trademark Office allows a patent application within ‘Esau’ patent family

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), announced today that the United States Patent and Trademark Office (USPTO) has allowed a patent application within the ‘Esau’ patent family (US Application Serial No. 10/909,125).

28 Oct 2009

Pure Protein develops soluble Class II human leukocyte antigens

Pure Protein, L.L.C., a biopharmaceutical company specializing in diagnostic and therapeutic reagents for use in immunology research and development, has announced that Chief Scientist William Hildebrand, Ph.D., and his team, have developed soluble Class II human leukocyte antigens (HLA). This represents a significant technology breakthrough that can dramatically impact multiple pharmaceutical and medical sectors and has enormous market potential. Autoimmune disease is a key area of interest for HLA research and product development.

28 Oct 2009

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study.

28 Oct 2009

Fastest supercomputer used to create an evolutionary genetic HIV family tree

Supporting Los Alamos National Laboratory's role in the international Center for HIV/AIDS Vaccine Immunology (CHAVI) consortium, researchers are using the Roadrunner supercomputer to analyze vast quantities of genetic sequences from HIV infected people in the hope of zeroing in on possible vaccine target areas.

28 Oct 2009

NCKU transfers microalgal docosahexaenoic acid production technology to Vedan Biotechnology

NCKU President, Academician Michael Ming-Chiao Lai, signed Technology Transfer Agreement in this morning with Mr. Tou-Hsiung Yang, Chairman of Vedan International (Holding) Ltd, witnessed by Vedan Biotechnology President Shih-An (Raymond) Yang and the inventor, Prof. Huey-Lang Yang of the NCKU Institute of Biotechnology.

28 Oct 2009

National Heart, Lung and Blood Institutes funds multi-year project

Scientists at the Gladstone Institute of Cardiovascular Disease (GICD) will receive $10 million over the next 6 years to find the genetic causes of congenital heart disease.

28 Oct 2009

Starting Grant from ERC to LMU junior researchers

Two junior researchers from Ludwig-Maximilians-Universit-t (LMU) in Munich shall each receive a Starting Grant from the European Research Council (ERC). Professor Jens Michaelis, Department of Chemistry and Biochemistry, and Privatdozent Dr. David V-hringer, Institute of Immunology, shall receive grants amounting to 1.4 and 1.7 million Euros over five years. With its Starting Grant, the ERC supports highly creative researchers in order to encourage pioneering frontier research.

27 Oct 2009

Helicos Biosciences reports operational highlights for the third quarter of 2009

Helicos BioSciences Corporation announced today its operational, technical and scientific highlights for the quarter ended September 30, 2009.

27 Oct 2009

Astellas enters into agreement with Medivation to develop MDV3100

Astellas Pharma Inc. ("Astellas") and Medivation, Inc. announced today that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer.

27 Oct 2009

NCMLS organises immunology congress at Nijmegen

How do cells in our immune system recognise dangerous invaders and hazardous cells, such as cancer cells? Answers to this and similar questions are evolving rapidly. A large contributor worldwide to the field of immunology is the NCMLS, Nijmegen Centre for Molecular Life Sciences of the Radboud University Nijmegen Medical Centre. The NCMLS is organising an important scientific congress on this very topic, for which the absolute world top immunology experts are coming to Nijmegen.

27 Oct 2009

New data from efficacy study of CIMZIA in Crohn's disease patients presented

New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years.

27 Oct 2009

eBioscience acquires privately held immunoassay technology pioneer Bender MedSystems

eBioscience Corporation today announced that it has acquired privately held immunoassay technology pioneer Bender MedSystems GmbH in an all cash transaction. The acquisition will provide eBioscience with over 1,000 high profile immunology and oncology products including the Instant ELISA® and FlowCytomix(TM) brands that target the life sciences and diagnostics markets.

27 Oct 2009

Wellcome Trust's 91M fund aims at developing new drugs related to the dengue fever virus

The Wellcome Trust spends over 600 million pounds each year to support its mission to foster and promote research with the aim to improving human and animal health. This funding supports basic research as well as technology transfer, the transfer of academic knowledge and technology to the corporate environment.

26 Oct 2009

Study on Pten's tumour suppressive functions published

Sanford Barsky, M.D., who holds faculty positions at the University of Nevada School of Medicine as chair of the pathology department and Nevada Cancer Institute chief of pathology, is part of a team that has a paper on transgenic mouse mammary tumors with direct relevance to human breast cancer published in the October 22 issue of the scientific journal Nature.

24 Oct 2009

UAB to create national database and repository to identify medications for rheumatoid arthritis

The University of Alabama at Birmingham (UAB) is spearheading an effort to create a national database and repository to enable researchers to identify predictors of effectiveness of various treatments for rheumatoid arthritis (RA).

24 Oct 2009

MPI Research to assist Kineta in autoimmune drug development program

MPI Research, a preclinical Contract Research Organization (CRO), announced that it will be collaborating with Kineta, Inc, a Seattle-based privately held biotechnology company specializing in clinical advancement of drugs that modulate and enhance the human immune system.

24 Oct 2009

Immunology News and Research

Latest Immunology News and Research

Cardiome Pharmam, Astellas Pharma begin patient enrolment for ACT 5 trial

USC researchers receive grant to develop stem cell-based treatment for age-related macular degeneration

Pregnant women with symptoms of depression have a stronger biological reaction to the seasonal flu vaccine

Lovelace Respiratory Research Institute and Brigham and Women's Hospital collaborate on respiratory diseases research

United States Patent and Trademark Office allows a patent application within ‘Esau’ patent family

Pure Protein develops soluble Class II human leukocyte antigens

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

Fastest supercomputer used to create an evolutionary genetic HIV family tree

NCKU transfers microalgal docosahexaenoic acid production technology to Vedan Biotechnology

National Heart, Lung and Blood Institutes funds multi-year project

Starting Grant from ERC to LMU junior researchers

Helicos Biosciences reports operational highlights for the third quarter of 2009

Astellas enters into agreement with Medivation to develop MDV3100

NCMLS organises immunology congress at Nijmegen

New data from efficacy study of CIMZIA in Crohn's disease patients presented

eBioscience acquires privately held immunoassay technology pioneer Bender MedSystems

Wellcome Trust's 91M fund aims at developing new drugs related to the dengue fever virus

Study on Pten's tumour suppressive functions published

UAB to create national database and repository to identify medications for rheumatoid arthritis

MPI Research to assist Kineta in autoimmune drug development program

Industry Focus eBook - Immunology (1st Edition) eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research